首页|CXCL16 promotes proliferation of head and neck squamous cell carcinoma by regulating GPX1-mediated antioxidant levels

CXCL16 promotes proliferation of head and neck squamous cell carcinoma by regulating GPX1-mediated antioxidant levels

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Numerous studies have demonstrated that the high expression of CXC motif chemokine ligand 16(CXCL16)in cancer correlates with poor prognosis,as well as tumor cell proliferation,migration,and invasion.While CXCL16 can serve as a tumor biomarker,the underlying mechanism in modulating head and neck squamous cell carcinoma(HNSCC)remains unclear.In this study,the aimed was to investigate the CXCL16 expression in HNSCC and to uncover the potential underlying mechanism.Hereby,we determined the high expression of CXCL16 in The Cancer Genome Atlas(TCGA)database,as well as in tissue samples from patients with HNSCC at our central hospital and from HNSCC cell lines.The results showed that CXCL16 knockdown inhibited the proliferation,migration,and invasion of HNSCC cells.Mechanistically,transcriptome sequencing revealed that CXCL16 may affect HNSCC cell growth by regulating the antioxidant pathway of glutathione peroxidase 1(GPX1).The reactive oxygen species(ROS)levels were elevated in small interfering CXCL16(si-CXCL16)cells,which may contribute to the inhibition of cell proliferation,migration,and invasion.Moreover,treatment of cells with the GPX1 inhibitor eldecalcitol(ED-71)revealed that HNSCC cell growth was significantly inhibited in the synergistic group of si-CXCL16 and GPX1 inhibitor compared to the si-CXCL16 group.In conclusion,CXCL16 contributed to the development of HNSCC cells by modulating the GPX1-mediated antioxidant pathway.Thus,targeting cellular CXCL16 expression seems to be a promising strategy for treating HNSCC.

Antioxidant pathwayCXC motif chemokine ligand 16(CXCL16)Glutathione peroxidase 1(GPX1)Head and neck squamous cell carcinoma(HNSCC)

Ru HE、Hongyi JIANG、Chengchi ZHANG、Yuan CHEN、Wenshun LIU、Xinyue DENG、Xiaozheng ZHU、Yunye LIU、Chuanming ZHENG、Yining ZHANG、Chengying SHAO、Yanting DUAN、Jiajie XU

展开 >

Otolaryngology&Head and Neck Center,Cancer Center,Department of Head and Neck Surgery,Zhejiang Provincial People's Hospital(Affiliated People's Hospital),Hangzhou Medical College,Hangzhou 310014,China

Zhejiang Key Laboratory of Precision Medicine Research on Head&Neck Cancer,Hangzhou 310014,China

College of Biotechnology and Bioengineering,Zhejiang University of Technology,Hangzhou 310014,China

Cancer Center,Department of Pathology,Zhejiang Provincial People's Hospital(Affiliated People's Hospital),Hangzhou Medical College,Hangzhou 310014,China

Department of Postgraduate Education,Jinzhou Medical University,Jinzhou 121000,China

The Second School of Clinical Medicine,Zhejiang Chinese Medical University,Hangzhou 310053,China

展开 >

2025

10.1631/jzus.B2400192

浙江大学学报(英文版)(B辑:生物医学和生物技术)
浙江大学

浙江大学学报(英文版)(B辑:生物医学和生物技术)

影响因子：0.798
ISSN：1673-1581
年,卷(期)：2025.26(1)